NanoViricides, Inc. — Form 10-Q Summary
Business context and reporting period
The filing is a quarterly report for the period ended March 31, 2014, covering the company’s fiscal third quarter and first nine months of fiscal 2014. Although the request metadata labels this “2013 Q3,” the filing itself reports 2014 results; investors should confirm the intended period. NanoViricides is a development-stage antiviral drug company with no commercialized products or revenue.
Financial performance and position
| Metric | Three months ended March 31, 2014 | Nine months ended March 31, 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $625,737 | $2,930,436 |
| General and administrative expense | $607,628 | $1,943,123 |
| Operating loss | $1,233,365 | $4,873,559 |
| Net loss | $294,410 | $8,259,572 |
| Basic and diluted loss per share | $0.01 | $0.16 |
At March 31, 2014, cash and cash equivalents were $33.3 million; current assets were $34.6 million, against current liabilities of $1.2 million. Working capital was approximately $33.4 million. The company also reported a $2.0 million security deposit related to the planned Shelton facility. Total assets were $40.9 million and stockholders’ equity was $32.0 million.
Long-term liabilities included $3.9 million of convertible debentures and a $3.8 million derivative liability. The $6.0 million principal debentures bear 8% interest, mature January 31, 2017, and are convertible into common shares. Cash used in operations was $5.4 million for the nine months; cash used in investing was $4.6 million, including $3.6 million for property and equipment and $1.0 million additional collateral. Financing activities provided $29.3 million, principally from common-stock and warrant offerings and warrant exercises.
Changes versus the prior comparable period
- Third-quarter net loss narrowed to $0.3 million from $3.7 million a year earlier. Operating expenses fell to $1.2 million from $2.2 million, including lower R&D expense. A $3.8 million favorable change in derivative fair value was a major factor in the smaller quarterly net loss; interest expense was also substantially higher.
- For the nine months, net loss increased to $8.3 million from $6.7 million, despite a modest decrease in operating expenses. Interest expense rose to $3.0 million from $0.8 million, and the derivative fair-value change was less favorable than in the prior year.
- Cash increased from $13.9 million at June 30, 2013 to $33.3 million at March 31, 2014, mainly following equity financings. Common shares outstanding rose from 47.0 million to 54.5 million during that period.
- Cash used in operations rose to $5.4 million from $4.4 million for the comparable nine months. The filing also reports $2.6 million of debenture interest paid in shares, a noncash item.
Outlook, commentary, risks and contingencies
Management estimated that available cash and collateral would fund operations through at least March 31, 2016 at the then-current spending rate. It also said current resources were expected to support toxicology and additional animal studies, an IND-stage program, and Phase I/IIa trials for at least one candidate, while acknowledging that estimates rely on outside-party quotes and may be materially inaccurate. The filing anticipates substantial future spending, including research and development, staffing, facility costs and clinical trials; additional financing may be needed, and the company may reprioritize programs if funds or costs differ from expectations.
Management described injectable FluCide as the most advanced program. A preliminary non-GLP safety study was reported as showing no adverse findings; GLP safety and toxicology work remained planned before an IND submission. DengueCide had received US and European orphan-drug designations. HIVCide, oral FluCide, herpes, eye-disease and other antiviral programs remained in preclinical development. These are company-reported development claims, not evidence of clinical efficacy or approval.
The company had not finalized a lease or purchase agreement for the related-party Shelton manufacturing facility. It had provided $2.0 million of cash collateral for Inno-Haven’s borrowing and reported spending on facility improvements; Inno-Haven is controlled by company founder and chairman Anil Diwan. TheraCour, the principal technology licensor and a related party, charges development costs and holds manufacturing rights under the license arrangements. The filing reports $1.7 million of TheraCour development charges for the nine-month period.
The company reported ongoing shareholder litigation in Nevada and Colorado. It said no monetary accrual was recorded, describing the claims as without merit; motions remained pending in the Nevada case. Principal risks include no revenue, recurring losses, uncertain drug-development timelines and outcomes, regulatory and manufacturing hurdles, dependence on related parties and external service providers, possible additional financing and dilution, and potential cost overruns. The filing states that no reportable subsequent events were identified through issuance.
Most important facts for investors to verify
- Confirm the correct reporting period: the filing covers the quarter ended March 31, 2014, notwithstanding the “2013 Q3” request label.
- Reconcile the facility-improvement disclosures: the filing gives differing descriptions and amounts, including approximately $1.1 million, $3.1 million and $3.6 million, and clarify the accounting treatment and collateral exposure.
- Review the debenture conversion terms, share-based interest obligations, derivative valuation and potential dilution from outstanding warrants and other convertible securities.
- Validate management’s runway and clinical-development cost assumptions, including the status and expected cost of GLP studies, IND preparation and any clinical trials.
- Review related-party arrangements and the final ownership, lease or purchase terms for the Shelton facility, including the $2.0 million cash collateral and pledged shares.
- Check current status and potential consequences of the Nevada and Colorado litigation, and confirm whether any later developments changed the filing’s disclosures.